Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droperidol for Modulating Fentanyl Drug Liking in Peri-procedural Settings
NCT07015528Phase 1Enrolling by invitation
- Sponsor
- Stanford University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Droperidol with Placebo (2 arms). Primary endpoint: Change in Drug Liking Rating at 5 months. Started Sep 2025; status: enrolling by invitation.
02
Drugs
droperidol
Beyond the preview
Go deeper on NCT07015528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015528.